SC
PACB icon

Scholtz & Company’s Pacific Biosciences PACB Stock Holding History

Scholtz & Company’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,165
Closed -$216K – 74
2021
Q2 		$216K Sell
6,165
-3,370
-35% -$98K 0.07% 69
2021
Q1 		$318K Buy
+9,535
New +$334K 0.12% 61

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Scholtz & Company's PACB Position: Q3 2021 in Review

Scholtz & Company sold out of Pacific Biosciences (PACB) in Q3 2021, closing a stake of 6,165 shares — an estimated $216K sold.

Scholtz & Company first reported a position in PACB in Q1 2021 and held it in 2 quarters. The position peaked at $318K in Q1 2021. 246 funds tracked by Wall St. Rank hold PACB as of Q3 2021.

  • Scholtz & Company reported no remaining Pacific Biosciences position as of Q3 2021 after selling out during the quarter.
  • Scholtz & Company sold 6,165 Pacific Biosciences shares in Q3 2021, an estimated $216K.
  • Scholtz & Company first reported a position in Pacific Biosciences in Q1 2021 and held it in 2 quarters.
  • Scholtz & Company's Pacific Biosciences position peaked at $318K in Q1 2021.
  • 246 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2021.

Based on Scholtz & Company's 13F filing for Q3 2021, filed 15 Nov 2021.